Which has higher earnings and valuation, ADMA or ACET?

ADMA Biologics has higher revenue and earnings than Adicet Bio. Adicet Bio is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ADMA Biologics $512.28M 3.98 $146.93M $0.70 13.01 Adicet Bio N/A N/A -$116.80M -$11.45 N/A

Is ADMA or ACET more profitable?

ADMA Biologics has a net margin of 32.98% compared to Adicet Bio's net margin of 0.00%. ADMA Biologics' return on equity of 40.17% beat Adicet Bio's return on equity. Company Net Margins Return on Equity Return on Assets ADMA Biologics 32.98% 40.17% 26.97% Adicet Bio N/A -74.90% -60.87%

Does the media refer more to ADMA or ACET?

In the previous week, Adicet Bio had 2 more articles in the media than ADMA Biologics. MarketBeat recorded 5 mentions for Adicet Bio and 3 mentions for ADMA Biologics. Adicet Bio's average media sentiment score of 0.48 beat ADMA Biologics' score of 0.33 indicating that Adicet Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ADMA Biologics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Adicet Bio 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation & earnings, SION or ACET?

Sionna Therapeutics is trading at a lower price-to-earnings ratio than Adicet Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sionna Therapeutics N/A N/A -$75.27M -$2.18 N/A Adicet Bio N/A N/A -$116.80M -$11.45 N/A

Is SION or ACET more profitable?

Sionna Therapeutics' return on equity of -32.94% beat Adicet Bio's return on equity. Company Net Margins Return on Equity Return on Assets Sionna Therapeutics N/A -32.94% -31.08% Adicet Bio N/A -74.90% -60.87%

Does the media favor SION or ACET?

In the previous week, Sionna Therapeutics had 9 more articles in the media than Adicet Bio. MarketBeat recorded 14 mentions for Sionna Therapeutics and 5 mentions for Adicet Bio. Adicet Bio's average media sentiment score of 0.48 beat Sionna Therapeutics' score of 0.00 indicating that Adicet Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sionna Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral Adicet Bio 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is IPSC or ACET more profitable?

Century Therapeutics' return on equity of -49.51% beat Adicet Bio's return on equity. Company Net Margins Return on Equity Return on Assets Century Therapeutics N/A -49.51% -38.09% Adicet Bio N/A -74.90% -60.87%

Does the media favor IPSC or ACET?

In the previous week, Adicet Bio had 2 more articles in the media than Century Therapeutics. MarketBeat recorded 5 mentions for Adicet Bio and 3 mentions for Century Therapeutics. Adicet Bio's average media sentiment score of 0.48 beat Century Therapeutics' score of -0.06 indicating that Adicet Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Century Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Adicet Bio 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation & earnings, DMAC or ACET?

DiaMedica Therapeutics is trading at a lower price-to-earnings ratio than Adicet Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio DiaMedica Therapeutics N/A N/A -$32.77M -$0.72 N/A Adicet Bio N/A N/A -$116.80M -$11.45 N/A

Is DMAC or ACET more profitable?

Adicet Bio's return on equity of -74.90% beat DiaMedica Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets DiaMedica Therapeutics N/A -77.76% -69.43% Adicet Bio N/A -74.90% -60.87%

Does the media refer more to DMAC or ACET?

In the previous week, Adicet Bio had 3 more articles in the media than DiaMedica Therapeutics. MarketBeat recorded 5 mentions for Adicet Bio and 2 mentions for DiaMedica Therapeutics. Adicet Bio's average media sentiment score of 0.48 beat DiaMedica Therapeutics' score of 0.00 indicating that Adicet Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DiaMedica Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Adicet Bio 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings and valuation, ACET or LXEO?

Lexeo Therapeutics is trading at a lower price-to-earnings ratio than Adicet Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Adicet Bio N/A N/A -$116.80M -$11.45 N/A Lexeo Therapeutics N/A N/A -$99.96M -$1.15 N/A

Is ACET or LXEO more profitable?

Lexeo Therapeutics' return on equity of -41.85% beat Adicet Bio's return on equity. Company Net Margins Return on Equity Return on Assets Adicet Bio N/A -74.90% -60.87% Lexeo Therapeutics N/A -41.85% -38.03%

Does the media prefer ACET or LXEO?

In the previous week, Adicet Bio had 3 more articles in the media than Lexeo Therapeutics. MarketBeat recorded 5 mentions for Adicet Bio and 2 mentions for Lexeo Therapeutics. Lexeo Therapeutics' average media sentiment score of 0.67 beat Adicet Bio's score of 0.48 indicating that Lexeo Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adicet Bio 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Lexeo Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Adicet Bio (ACET) Competitors

$9.18 +0.17 (+1.89%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$9.07 -0.11 (-1.19%)

As of 09/18/2026 07:48 PM Eastern

Compare

ACET vs. ADMA, SION, IPSC, DMAC, and LXEO

Should you buy Adicet Bio stock or one of its competitors? Adicet Bio's main competitors and comparable companies include ADMA Biologics (ADMA), Sionna Therapeutics (SION), Century Therapeutics (IPSC), DiaMedica Therapeutics (DMAC), and Lexeo Therapeutics (LXEO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Adicet Bio compare to ADMA Biologics?

ADMA Biologics (NASDAQ:ADMA) and Adicet Bio (NASDAQ:ACET) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, profitability, risk, earnings, dividends and institutional ownership.

ADMA Biologics has higher revenue and earnings than Adicet Bio. Adicet Bio is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ADMA Biologics	$512.28M	3.98	$146.93M	$0.70	13.01
Adicet Bio	N/A	N/A	-$116.80M	-$11.45	N/A

In the previous week, Adicet Bio had 2 more articles in the media than ADMA Biologics. MarketBeat recorded 5 mentions for Adicet Bio and 3 mentions for ADMA Biologics. Adicet Bio's average media sentiment score of 0.48 beat ADMA Biologics' score of 0.33 indicating that Adicet Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ADMA Biologics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Adicet Bio	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

ADMA Biologics currently has a consensus price target of $18.67, suggesting a potential upside of 104.90%. Adicet Bio has a consensus price target of $46.80, suggesting a potential upside of 409.80%. Given Adicet Bio's stronger consensus rating and higher possible upside, analysts clearly believe Adicet Bio is more favorable than ADMA Biologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ADMA Biologics	0 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Adicet Bio	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.88

ADMA Biologics has a net margin of 32.98% compared to Adicet Bio's net margin of 0.00%. ADMA Biologics' return on equity of 40.17% beat Adicet Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ADMA Biologics	32.98%	40.17%	26.97%
Adicet Bio	N/A	-74.90%	-60.87%

ADMA Biologics has a beta of 0.78, meaning that its share price is 22% less volatile than the broader market. Comparatively, Adicet Bio has a beta of 1.58, meaning that its share price is 58% more volatile than the broader market.

75.7% of ADMA Biologics shares are owned by institutional investors. Comparatively, 83.9% of Adicet Bio shares are owned by institutional investors. 3.9% of ADMA Biologics shares are owned by company insiders. Comparatively, 3.4% of Adicet Bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

ADMA Biologics and Adicet Bio tied by winning 8 of the 16 factors compared between the two stocks.

How does Adicet Bio compare to Sionna Therapeutics?

Sionna Therapeutics (NASDAQ:SION) and Adicet Bio (NASDAQ:ACET) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, media sentiment, earnings, risk and dividends.

Sionna Therapeutics presently has a consensus target price of $42.33, suggesting a potential upside of 610.29%. Adicet Bio has a consensus target price of $46.80, suggesting a potential upside of 409.80%. Given Sionna Therapeutics' higher possible upside, equities research analysts clearly believe Sionna Therapeutics is more favorable than Adicet Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sionna Therapeutics	1 Sell rating(s)	11 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Adicet Bio	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.88

Sionna Therapeutics has a beta of 0.89, indicating that its stock price is 11% less volatile than the broader market. Comparatively, Adicet Bio has a beta of 1.58, indicating that its stock price is 58% more volatile than the broader market.

In the previous week, Sionna Therapeutics had 9 more articles in the media than Adicet Bio. MarketBeat recorded 14 mentions for Sionna Therapeutics and 5 mentions for Adicet Bio. Adicet Bio's average media sentiment score of 0.48 beat Sionna Therapeutics' score of 0.00 indicating that Adicet Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sionna Therapeutics	1 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral
Adicet Bio	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Sionna Therapeutics' return on equity of -32.94% beat Adicet Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sionna Therapeutics	N/A	-32.94%	-31.08%
Adicet Bio	N/A	-74.90%	-60.87%

83.9% of Adicet Bio shares are held by institutional investors. 5.1% of Sionna Therapeutics shares are held by insiders. Comparatively, 3.4% of Adicet Bio shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Sionna Therapeutics is trading at a lower price-to-earnings ratio than Adicet Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sionna Therapeutics	N/A	N/A	-$75.27M	-$2.18	N/A
Adicet Bio	N/A	N/A	-$116.80M	-$11.45	N/A

Summary

Sionna Therapeutics and Adicet Bio tied by winning 7 of the 14 factors compared between the two stocks.

How does Adicet Bio compare to Century Therapeutics?

Century Therapeutics (NASDAQ:IPSC) and Adicet Bio (NASDAQ:ACET) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, media sentiment, risk, analyst recommendations, earnings, institutional ownership, valuation and dividends.

Century Therapeutics' return on equity of -49.51% beat Adicet Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Century Therapeutics	N/A	-49.51%	-38.09%
Adicet Bio	N/A	-74.90%	-60.87%

50.2% of Century Therapeutics shares are held by institutional investors. Comparatively, 83.9% of Adicet Bio shares are held by institutional investors. 2.4% of Century Therapeutics shares are held by company insiders. Comparatively, 3.4% of Adicet Bio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Century Therapeutics currently has a consensus target price of $4.75, suggesting a potential upside of 155.38%. Adicet Bio has a consensus target price of $46.80, suggesting a potential upside of 409.80%. Given Adicet Bio's stronger consensus rating and higher possible upside, analysts clearly believe Adicet Bio is more favorable than Century Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Century Therapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Adicet Bio	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.88

Century Therapeutics has higher revenue and earnings than Adicet Bio. Century Therapeutics is trading at a lower price-to-earnings ratio than Adicet Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Century Therapeutics	$109.16M	3.09	-$9.58M	-$0.93	N/A
Adicet Bio	N/A	N/A	-$116.80M	-$11.45	N/A

In the previous week, Adicet Bio had 2 more articles in the media than Century Therapeutics. MarketBeat recorded 5 mentions for Adicet Bio and 3 mentions for Century Therapeutics. Adicet Bio's average media sentiment score of 0.48 beat Century Therapeutics' score of -0.06 indicating that Adicet Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Century Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Adicet Bio	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Century Therapeutics has a beta of 1.59, indicating that its stock price is 59% more volatile than the broader market. Comparatively, Adicet Bio has a beta of 1.58, indicating that its stock price is 58% more volatile than the broader market.

Summary

Adicet Bio beats Century Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Adicet Bio compare to DiaMedica Therapeutics?

DiaMedica Therapeutics (NASDAQ:DMAC) and Adicet Bio (NASDAQ:ACET) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, risk, dividends, media sentiment and earnings.

DiaMedica Therapeutics is trading at a lower price-to-earnings ratio than Adicet Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DiaMedica Therapeutics	N/A	N/A	-$32.77M	-$0.72	N/A
Adicet Bio	N/A	N/A	-$116.80M	-$11.45	N/A

DiaMedica Therapeutics presently has a consensus price target of $12.00, suggesting a potential upside of 75.18%. Adicet Bio has a consensus price target of $46.80, suggesting a potential upside of 409.80%. Given Adicet Bio's stronger consensus rating and higher possible upside, analysts plainly believe Adicet Bio is more favorable than DiaMedica Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DiaMedica Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Adicet Bio	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.88

10.1% of DiaMedica Therapeutics shares are held by institutional investors. Comparatively, 83.9% of Adicet Bio shares are held by institutional investors. 5.0% of DiaMedica Therapeutics shares are held by company insiders. Comparatively, 3.4% of Adicet Bio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Adicet Bio had 3 more articles in the media than DiaMedica Therapeutics. MarketBeat recorded 5 mentions for Adicet Bio and 2 mentions for DiaMedica Therapeutics. Adicet Bio's average media sentiment score of 0.48 beat DiaMedica Therapeutics' score of 0.00 indicating that Adicet Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DiaMedica Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Adicet Bio	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

DiaMedica Therapeutics has a beta of 0.98, meaning that its stock price is 2% less volatile than the broader market. Comparatively, Adicet Bio has a beta of 1.58, meaning that its stock price is 58% more volatile than the broader market.

Adicet Bio's return on equity of -74.90% beat DiaMedica Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DiaMedica Therapeutics	N/A	-77.76%	-69.43%
Adicet Bio	N/A	-74.90%	-60.87%

Summary

Adicet Bio beats DiaMedica Therapeutics on 10 of the 13 factors compared between the two stocks.

How does Adicet Bio compare to Lexeo Therapeutics?

Adicet Bio (NASDAQ:ACET) and Lexeo Therapeutics (NASDAQ:LXEO) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, analyst recommendations, media sentiment, earnings, risk, dividends, profitability and institutional ownership.

Adicet Bio currently has a consensus price target of $46.80, suggesting a potential upside of 409.80%. Lexeo Therapeutics has a consensus price target of $18.75, suggesting a potential upside of 346.43%. Given Adicet Bio's higher probable upside, analysts plainly believe Adicet Bio is more favorable than Lexeo Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adicet Bio	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.88
Lexeo Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	3.00

Lexeo Therapeutics' return on equity of -41.85% beat Adicet Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adicet Bio	N/A	-74.90%	-60.87%
Lexeo Therapeutics	N/A	-41.85%	-38.03%

Lexeo Therapeutics is trading at a lower price-to-earnings ratio than Adicet Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adicet Bio	N/A	N/A	-$116.80M	-$11.45	N/A
Lexeo Therapeutics	N/A	N/A	-$99.96M	-$1.15	N/A

Adicet Bio has a beta of 1.58, meaning that its share price is 58% more volatile than the broader market. Comparatively, Lexeo Therapeutics has a beta of 1.5, meaning that its share price is 50% more volatile than the broader market.

In the previous week, Adicet Bio had 3 more articles in the media than Lexeo Therapeutics. MarketBeat recorded 5 mentions for Adicet Bio and 2 mentions for Lexeo Therapeutics. Lexeo Therapeutics' average media sentiment score of 0.67 beat Adicet Bio's score of 0.48 indicating that Lexeo Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Adicet Bio	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Lexeo Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

83.9% of Adicet Bio shares are owned by institutional investors. Comparatively, 60.7% of Lexeo Therapeutics shares are owned by institutional investors. 3.4% of Adicet Bio shares are owned by insiders. Comparatively, 2.0% of Lexeo Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Lexeo Therapeutics beats Adicet Bio on 7 of the 13 factors compared between the two stocks.

Get Adicet Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ACET and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ACET vs. The Competition

Export

Metric	Adicet Bio	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$85.94M	$3.89B	$7.24B	$13.21B
Dividend Yield	N/A	3.64%	2.57%	12.81%
P/E Ratio	-0.80	14.23	275.49	25.40
Price / Sales	N/A	1,419.61	639.63	86.91
Price / Cash	N/A	108.90	76.25	51.42
Price / Book	0.55	15.45	10.46	6.33
Net Income	-$116.80M	-$22.86M	$3.49B	$358.33M
7 Day Performance	-3.57%	-1.21%	0.59%	1.12%
1 Month Performance	-2.13%	-3.29%	-1.74%	-2.39%
1 Year Performance	-27.81%	37.74%	18.13%	5.35%

Adicet Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ACET Adicet Bio	3.9407 of 5 stars	$9.18 +1.9%	$46.80 +409.8%	-27.8%	$85.94M	N/A	N/A	102	News Coverage Analyst Forecast
ADMA ADMA Biologics	3.0163 of 5 stars	$9.14 -1.0%	$18.67 +104.2%	-42.7%	$2.07B	$510.17M	13.06	647
SION Sionna Therapeutics	3.1526 of 5 stars	$8.26 +5.2%	$42.22 +411.2%	-74.2%	$354.92M	N/A	N/A	59	Analyst Forecast
IPSC Century Therapeutics	1.4163 of 5 stars	$2.00 +3.1%	$4.75 +137.5%	+289.8%	$351.29M	N/A	N/A	78	News Coverage
DMAC DiaMedica Therapeutics	1.3715 of 5 stars	$6.55 +1.2%	$12.00 +83.2%	+0.4%	$348.90M	N/A	N/A	35	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ACET) was last updated on 9/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Adicet Bio (ACET) Competitors

ACET vs. ADMA, SION, IPSC, DMAC, and LXEO

How does Adicet Bio compare to ADMA Biologics?

Summary

How does Adicet Bio compare to Sionna Therapeutics?

Summary

How does Adicet Bio compare to Century Therapeutics?

Summary

How does Adicet Bio compare to DiaMedica Therapeutics?

Summary

How does Adicet Bio compare to Lexeo Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACET vs. The Competition

Adicet Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Adicet Bio (ACET) Competitors

ACET vs. ADMA, SION, IPSC, DMAC, and LXEO

How does Adicet Bio compare to ADMA Biologics?

Which has higher earnings and valuation, ADMA or ACET?

Does the media refer more to ADMA or ACET?

Do analysts recommend ADMA or ACET?

Is ADMA or ACET more profitable?

Which has more risk and volatility, ADMA or ACET?

Do insiders and institutionals hold more shares of ADMA or ACET?

Summary

How does Adicet Bio compare to Sionna Therapeutics?

Do analysts prefer SION or ACET?

Which has more volatility & risk, SION or ACET?

Does the media favor SION or ACET?

Is SION or ACET more profitable?

Do insiders & institutionals have more ownership in SION or ACET?

Which has higher valuation & earnings, SION or ACET?

Summary

How does Adicet Bio compare to Century Therapeutics?

Is IPSC or ACET more profitable?

Do institutionals & insiders hold more shares of IPSC or ACET?

Do analysts rate IPSC or ACET?

Which has better valuation and earnings, IPSC or ACET?

Does the media favor IPSC or ACET?

Which has more risk & volatility, IPSC or ACET?

Summary

How does Adicet Bio compare to DiaMedica Therapeutics?

Which has stronger valuation & earnings, DMAC or ACET?

Do analysts prefer DMAC or ACET?

Do insiders and institutionals have more ownership in DMAC or ACET?

Does the media refer more to DMAC or ACET?

Which has more risk & volatility, DMAC or ACET?

Is DMAC or ACET more profitable?

Summary

How does Adicet Bio compare to Lexeo Therapeutics?

Do analysts recommend ACET or LXEO?

Is ACET or LXEO more profitable?

Which has preferable earnings and valuation, ACET or LXEO?

Which has more risk & volatility, ACET or LXEO?

Does the media prefer ACET or LXEO?

Do insiders & institutionals hold more shares of ACET or LXEO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACET vs. The Competition

Adicet Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools